Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2020 Financial Results on November 10, 2020

NEXT STORY
North Americaportable oxygen concentratorsmarket is expected to reach US$ 1,315.42 million by 2027 from US$ 682.73 million in 2019
PREV STORY
Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed Improved Overall Survival in Patients with Locally Advanced Pancreatic Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Coherus BioSciences Completes two Pharmacokinetic Bioequivalence Studies of CHS-0214

REDWOOD CITY, Calif., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) a ...

author_avatar
NASDAQ Market News

Novartis’ combination therapy Tafinlar® + Mekinist® granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma

Priority Review designation based on Phase III study showing 53% reduction in risk of ...

author_avatar
NASDAQ Market News

AB Science announces positive top-line Phase 2B/3 results for oral masitinib in progressive forms of multiple sclerosis

author_avatar
NASDAQ Market News